Xenon Pharmaceuticals (XENE) closed at $36.01 on Oct 27, 2026, up 0.7% on the day. The stock is down 1.9% over the past month, down 42.9% over three months, down 19.7% year to date and down 14.0% over the past year (since Oct 27, 2025). It trades 50.4% below its 52-week high of $72.66 and 7.9% above its 52-week low of $33.38. The close sits below its 50-day moving average ($46.83) and below its 200-day moving average ($52.43).
No — the Oct 27, 2026 close of $36.01 is 31.3% below the 200-day average of $52.43.
XENE closed 50.4% below its 52-week high of $72.66.
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
